Biocon Limited

Bajaj Allianz Life Insurance bought 6,500,022 shares of Biocon Limited for ₹25.03 Cr at ₹385.00 apiece in a block deal.

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

Now wholly owned by Bajaj Finserv after the Bajaj Group bought out Allianz SE's 26% stake in March 2025 for Rs 24,180 crore. Total AUM over Rs 1.2 lakh crore. Flagship Pure Stock Fund manages over Rs 7,200 crore as a Shariah-compliant Indian equity book. Active investor across large and midcap names through ULIP and group fund vehicles.